-- 据彭博社周一援引知情人士报道，摩根大通（JPM）、摩根士丹利（MS）和丹麦银行正在为利奥制药（Leo Pharma）在丹麦的潜在首次公开募股（IPO）做准备。 消息人士告诉彭博社，IPO可能在今年进行，利奥制药可能会聘请更多银行参与此次发行。报道称，由于尚未做出最终决定，计划仍有可能发生变化。 彭博社称，利奥制药2021年的估值约为30亿欧元（35.1亿美元），其中包括债务。 摩根大通、摩根士丹利、丹麦银行和利奥制药均未立即回复的置评请求。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息被认为是来自可靠来源，但可能包含传闻和猜测。准确性无法保证。）
Price: $307.98, Change: $-1.89, Percent Change: -0.61%
(Updates to add stock movement in the headline and last paragraph)Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.The company's shares fell 3% in recent Monday trade.
Alterity Therapeutics (ASX:ATH) said it received positive feedback from a second type C meeting with the US Food and Drug Administration (FDA) on its planned phase three program for drug candidate ATH434, aimed at treating multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.MSA is a progressive neurodegenerative disorder affecting autonomic and motor function with no approved disease-modifying therapies.The US FDA provided supportive written feedback on the program's chemistry, manufacturing, and controls, complementing earlier guidance from a separate type C meeting on clinical pharmacology and non-clinical development, the filing added.
Xinyuan Property Management Service's (HKG:1895) chief financial officer, Wang Yong, has resigned, effective April 26, according to a Monday Hong Kong bourse filing.Wang stepped down to devote more time to personal commitments, the company said.The company said the resignation will not affect its normal operations, with Wang's duties to be reallocated internally on an interim basis.Xinyuan Property Management added that it is seeking a suitable replacement for the chief financial officer role.